ArticleCancer immunology research2019
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 114 citations in OpenAlex.
- PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Trial
- PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.Leukemia · 2026Article
- Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Cancer research and treatment · 2026Article
- PD-1/TIGIT CD4⁺ T-Cell Signature for Risk Stratification of Post-Weaning Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients.Journal of inflammation research · 2026Article
- Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I.Discovery immunology · 2026Article
- Tumoral immune microenvironment profiling in B-cell non-Hodgkin lymphoma stratifies patients in different prognostic groups.Frontiers in immunology · 2026Article
- B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma.Cell communication and signaling : CCS · 2025Review
- Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.Cancer metastasis reviews · 2025Review
- Single-cell insights into the role of T cells in B-cell malignancies.FEBS letters · 2025Review
- Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response.Cancer immunology, immunotherapy : CII · 2025Article
- TIGIT/PVR axis regulates anti-tumor immunity in hematologic malignancies.Annals of hematology · 2025Review
- The future of immunotherapy for diffuse large B-cell lymphoma.International journal of cancer · 2025Review
- Identification and validation of ubiquitination-related genes for predicting cervical cancer outcome.Frontiers in genetics · 2025Article
- Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Frontiers in immunology · 2025Review
- Multimodal cell-cell communication driving CD8Frontiers in immunology · 2025Review
- Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal transduction and targeted therapy · 2024Review
- Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.Blood cancer journal · 2024Article
- Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation.NPJ breast cancer · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
Abstract
Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize antitumor T-cell responses. Here, characterization of coinhibitory receptor expression in intratumoral T cells from different NHL types identified TIGIT and PD-1 as frequently expressed coinhibitory receptors. Tumors from NHL patients were enriched in CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.